Libtayo (cemiplimab)
Numéro de dossier de l’AMC:
22694
État des négociations:
En négociation
Indication(s):
in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have no epidermal growth factor receptor (EGFR),
anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
anaplastic lymphoma kinase (ALK) or c‐ROS oncogene 1 (ROS1) aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC
Promoteur/fabricant:
Regeneron
Numéro de projet de l’AMC:
PC0331-000
Lettre d’entente de l’APP:
Conclusion du processus de négociation:
Sans objet